パーキンソン病におけるアルツハイマー病の特徴
Bárbara Fernandes Gomes1, Carly M Farris2, Yihua Ma2
1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
まとめ
アルファシヌクレインシード増幅測定法 (αSyn-SAA) はパーキンソン病 (PD) を正確に検出しますが,一部のPD患者では否定的になります. これらの否定的な症例は,アルツハイマー病 (AD) の運動サブタイプを表す可能性があります.
科学分野:
- 神経科学
- 神経学
- バイオマーカーの発見
背景:
- アルファ-シヌクレイン (αSyn) 種子増幅測定法 (αSyn-SAA) は,パーキンソン病 (PD) の敏感な診断ツールです.
- 臨床的に診断されたPD患者のサブセットは,αSyn-SAAで否定的な結果を出しており,根本的な病理に関するさらなる調査が必要である.
研究 の 目的:
- 様々な神経変性疾患におけるαSyn-SAAの診断性能を評価する.
- SAA経由でαSyn種子に対して陰性であるPD患者の臨床的および病理的表型を特徴づける.
主な方法:
- αSyn- SAAは,PD (n=93),多発性システム縮 (MSA,n=26),進行性超核性麻痺 (PSP,n=18),皮質基礎症候群 (n=3),および健康な対照群からの脳脊髄液 (CSF) のサンプルで実施された.
- αSyn- SAA陽性およびαSyn- SAA陰性PD患者の臨床表型とCSFのアミロイドβ42レベルを比較した.
主要な成果:
- αSyn-SAAは高精度で,90%のPD患者と81%のMSA患者でαSynを検出し,特異性は97%でした.
- αSyn- SAA- ネガティブのPD患者は,より重度の姿勢不安定性/ 歩行障害,エピソード性記憶障害を含む独特の臨床プロファイルを示した.
- αSyn- SAA- ネガティブのPD患者では,アミロイドβ42濃度の低下が観察され,SAA+ PSPの症例も独特の特徴を示した.
結論:
- PD患者のαSyn-SAAは,特定の臨床表現と関連しており,潜在的に併存するアルツハイマー病の病理性を示唆しています.
- これらの発見は,アルツハイマー病を運動障害の診断における重要な混乱要因として強調し,PDの臨床試験設計に影響を与えています.
- αSyn-SAAは堅固な測定法ですが,特定のPD症例におけるその限界は,ADのような代替または共同病理の検討を正当化します.
関連する概念動画
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K


